Navigation Links
Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma
Date:12/7/2009

lymphopenia (77%).

At active dose levels tested in this phase 1 clinical trial, permanent treatment discontinuation due to adverse events resulted mainly from fully reversible and transient neurological events during the first few days of treatment. A low ratio of B to T cells in peripheral blood was identified as a predictive biomarker for neurological events in patients with NHL. Based on these findings, and the possibility of adaptation of T cells by gradually increasing doses of blinatumomab, Micromet has developed a biomarker-guided dosing schedule designed to decrease the early neurological events and to provide all patients with the opportunity to reach the dose of 60 micrograms/squaremeter per day.

"We are very excited about the high response rate seen in patients with NHL treated at the 60-microgram dose level and are now planning larger studies to confirm these encouraging results," commented Dr. Jan Fagerberg, Micromet's Chief Medical Officer. "We expect that the biomarker-guided dosing schedule will accelerate the clinical development of blinatumomab in all relevant B-cell lymphoma indications."

(1) Nagorsen, D. et al. (2009) Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin's Lymphoma Patients Treated with 60 Microgram/Squaremeter per Day of BiTE Antibody Blinatumomab. ASH Annual Meeting, abstract no. 2723.

About BiTE Antibodies

BiTE® antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. BiTE antibodies have been shown to bind T cells to tumor cells, ultimately inducing a self-destruction process in the tumor cells referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially el
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting
2. Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability
3. New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology
4. Circassia Announces Successful Results From Phase II Clinical Study of ToleroMune(R) Cat Allergy Therapy
5. Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
6. Randy Olver Named Emdat CEO, Will Lead Next Phase of Growth for Medical Transcription Solutions Provider
7. NovaRx Corporation Announces FDA Approval of Protocol Amendment to Special Protocol Assessment (SPA) for Phase III Lucanix(R) Study in Non-Small Cell Lung Cancer (NSCLC)
8. AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer
9. Carmel Pharma Introduces PhaSeal Secondary Set (C60)
10. Carmel Pharma Introduces PhaSeal Secondary Set (C60)
11. AcelRx Announces Successful Completion of End-of-Phase 2 Meeting on ARX-01, Sufentanil NanoTab PCA System for Post-Operative Pain Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Fort Collins, CO (PRWEB) October 20, 2014 ... platform, dGH assays are the only imaging assays ... data in a single test.  With these three ... in their ability to detect the widest range ... chromosomal translocations—mutations usually missed by other genomic tools, ...
(Date:10/20/2014)... 2014 Unveiled at the Sept. 18 board ... conservatively estimates member hospital ROI on membership dues at 12.5. ... Center provides $12.50 in value to member hospitals. The calculation ... Member Dues)/Member Dues. , “This is the first time ... we think the methodology is really sound,” said Bill ...
(Date:10/20/2014)... October 20, 2014 Houston plastic surgeon ... the key elements of his innovative True Form ... plastic surgery residents and faculty at The University ... he, too, was once a medical student. Patronella, who ... private cosmetic plastic surgery practices in Texas, The ...
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, ... and GreenGeeks are the best Dedicated Server Hosting ... who want to buy high quality hosting and ... IT manager of Top10BestSEOHosting.com says, “We believe that ... for everyone. A lot of the global clients ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 This ... for Partial Seizure, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ... news and press releases. It also reviews key ... Seizure and special features on late-stage and discontinued ...
Breaking Medicine News(10 mins):Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4
... Ont., July 20, 2010--Most studies of healthcare for homeless people ... surprising that lack of money and insurance are the main ... have publicly funded universal health care? A new study ... _one in six _ reported unmet health care needs. ...
... 20, 2010) -- Chaos models may someday help model cardiac ... in the journal CHAOS, which is published by ... has drawn more attention to chaos in cardiac dynamics. Although ... origin of chaos and watching it develop might allow researchers ...
... WEDNESDAY, July 21 (HealthDay News) -- A two-step procedure that ... then inserts stem cells to promote healing of those arteries ... "One of the problems of removing plaque [with current ... the underlying wall," explained Dr. Edward A. Fisher, director of ...
... Most people know that high cholesterol levels place them at ... has shown that particular types of strokes contribute to one,s ... increase the risk of depression in the elderly. ... Biological Psychiatry , suggest the link between increased cholesterol and ...
... the journal Development , by Dr. Anthony-Samuel LaMantia, ... newly formed GW Institute for Neuroscience, and his colleagues ... classes of nerve cells olfactory receptors (ORNs), vomeronasal ... are responsible for enabling animals and humans, to eat, ...
... if an emergency room patient wants a different doctor than ... the patient is a woman or a racial minority, emergency ... a doctor of their same gender, race or religious background. ... System, along with colleagues from the University of Rochester and ...
Cached Medicine News:Health News:Toronto homeless report barriers to health care 2Health News:Procedure Rejuvenates Aging Arteries in Pigs 2Health News:Procedure Rejuvenates Aging Arteries in Pigs 3Health News:New links between cholesterol and depression in the elderly 2Health News:Researchers pinpoint key stem cells for eating and sex 2Health News:Women, minorities more likely to see doctor of choice in emergency room 2
(Date:10/20/2014)... Norgine B.V. today announced that ... bowel preparation, NER1006, presented at the 79 th ... (ACG), Philadelphia, PA , has met ... co-primary endpoint of cleansing success. The study demonstrated high ... in screening colonoscopy patients. [1] ...
(Date:10/19/2014)... 19, 2014 Große Pharmafirmen ... Das Problem dabei ist, dass große Pharmafirmen nicht ... zu teilen. Es war deshalb nicht ... uns umso mehr, dass es uns gelungen ist! ... Kühlketten aufzuschreiben - mit einem Vorbehalt - einige ...
(Date:10/17/2014)... OAKS, Calif. , Oct. 17, 2014  Amgen ... of R. Sanders Williams , M.D., president of ... Mahley Distinguished Professor.  "We are pleased ... Amgen Board," said Robert A. Bradway , chairman ... and distinguished experience in academic medicine and his direct ...
Breaking Medicine Technology:Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2Vergleichsbericht zu Pharma-Kühlketten und CRT 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3
Mini ReadySub-Cell GT Cell, includes buffer tank, lid and electrodes, leveling bubble; accommodates 8-well and 12-well mini ReadyAgarose gels...
The Large Gel Drying Kit dries gels using the same principal components as the DryEase Mini-Gel Drying System but can accommodate larger format gels or four mini-gels. A base is not required for asse...
... Preserve your data for future generations. Most ... the solid backing plate of our gel dryer, ... a frame over them to hold the cellophane ... a frame with an open area somewhat larger ...
... for future generations. Most gels can be dried ... of our gel dryer, covering them with wet ... to hold the cellophane flat. Tut's Tombs also ... open area somewhat larger than the gel to ...
Medicine Products: